Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 D
Go back to Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 D| (NASDAQ: APVO) | Delayed: 4.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.74 | 52 Week High | $4.33 | |||
| Open | $4.74 | 52 Week Low | $1.80 | |||
| Day High | $4.74 | P/E | N/A | |||
| Day Low | $4.74 | EPS | $0.00 | |||
| Volume | 4 | |||||
